Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H. Barouch, Ludo Lavreys, David Jetton et al.|The Lancet|2018Cited by 342
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)Lindsey R. Baden, Dan H. Barouch, Stephen R. Walsh et al.|The Journal of Infectious Diseases|2012Cited by 168
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)Dan H. Barouch, Lindsey R. Baden, Jinyan Liu et al.|The Journal of Infectious Diseases|2012Cited by 107
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 PreventionLindsey R. Baden, Etienne Karita, Gaudensia Mutua et al.|Annals of Internal Medicine|2016Cited by 84
Induction of HIV-1–Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of HumansLindsey R. Baden, Dan H. Barouch, Jinyan Liu et al.|The Journal of Infectious Diseases|2014Cited by 64